OHSS
MCID: OVR029
MIFTS: 61

Ovarian Hyperstimulation Syndrome (OHSS) malady

Categories: Genetic diseases, Reproductive diseases, Rare diseases

Aliases & Classifications for Ovarian Hyperstimulation Syndrome

Aliases & Descriptions for Ovarian Hyperstimulation Syndrome:

Name: Ovarian Hyperstimulation Syndrome 54 12 24 56 66 29 13 52 42 14 69
Ohss 24 56 66
Secondary Meig's Syndrome 12

Characteristics:

HPO:

32
ovarian hyperstimulation syndrome:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 54 608115
Disease Ontology 12 DOID:5425
MeSH 42 D016471
SNOMED-CT 64 129635004
Orphanet 56 ORPHA64739
MESH via Orphanet 43 D016471
UMLS via Orphanet 70 C0085083
ICD10 via Orphanet 34 N98.1
MedGen 40 C0085083
UMLS 69 C0085083

Summaries for Ovarian Hyperstimulation Syndrome

UniProtKB/Swiss-Prot : 66 Ovarian hyperstimulation syndrome: Disorder which occurs either spontaneously or most often as an iatrogenic complication of ovarian stimulation treatments for in vitro fertilization. The clinical manifestations vary from abdominal distention and discomfort to potentially life-threatening, massive ovarian enlargement and capillary leak with fluid sequestration. Pathologic features of this syndrome include the presence of multiple serous and hemorrhagic follicular cysts lined by luteinized cells, a condition called hyperreactio luteinalis.

MalaCards based summary : Ovarian Hyperstimulation Syndrome, also known as ohss, is related to endotheliitis and thrombosis, and has symptoms including abdominal pain, nausea and ascites. An important gene associated with Ovarian Hyperstimulation Syndrome is FSHR (Follicle Stimulating Hormone Receptor), and among its related pathways/superpathways are Development Endothelin-1/EDNRA signaling and Fluid shear stress and atherosclerosis. The drugs Progesterone and Estradiol have been mentioned in the context of this disorder. Affiliated tissues include endothelial, ovary and pituitary, and related phenotypes are homeostasis/metabolism and growth/size/body region

Wikipedia : 71 Ovarian hyperstimulation syndrome (OHSS) is a medical condition affecting the ovaries of some women who... more...

Description from OMIM: 608115

Related Diseases for Ovarian Hyperstimulation Syndrome

Diseases related to Ovarian Hyperstimulation Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 125)
id Related Disease Score Top Affiliating Genes
1 endotheliitis 10.6
2 thrombosis 10.4
3 craniosynostosis, type 1 10.3 IL6 VEGFA
4 degenerative disc disease 10.3 IL6 VEGFA
5 shoulder impingement syndrome 10.2 ALB IL6
6 submucous uterine fibroid 10.2 ALB VEGFA
7 hypersensitivity syndrome, carbamazepine-induced 10.2 ALB VEGFA
8 kidney osteogenic sarcoma 10.2 KDR VEGFA
9 cardiac tuberculosis 10.2 IL6 VEGFA
10 hand, foot and mouth disease 10.2 KDR VEGFA
11 supraumbilical midabdominal raphe and facial cavernous hemangiomas 10.2 F5 IL6
12 inner ear disease 10.2 ALB IL6
13 periodic fever, aphthous stomatitis, pharyngitis and adenitis 10.2 CGA GNRH1
14 hole retinal cyst 10.2 GNRH1 KDR
15 spondyloarthropathy 2 10.2 ALB VEGFA
16 cone-rod dystrophy 17 10.2 KDR VEGFA
17 glucosephosphate dehydrogenase deficiency 10.2 ALB IL6
18 ischemic optic neuropathy 10.2 ALB IL6 VEGFA
19 distal monosomy 14q 10.2 IL6 REN
20 histiocytoid hemangioma 10.2 ALB IL6 VEGFA
21 congenital chloride diarrhea 10.2 ALB IL6 VEGFA
22 bipolar i disorder 10.1 IL6 VEGFA
23 transsexualism 10.1 ALB REN
24 oppositional defiant disorder 10.1 IL6 KDR VEGFA
25 antiphospholipid syndrome 10.1 ALB REN
26 metagonimiasis 10.1 IL6 KDR VEGFA
27 vulvitis 10.1 IL6 KDR VEGFA
28 intramuscular hemangioma 10.1 AMH GNRH1
29 cryptosporidiosis 10.1 F5 IL6 VEGFA
30 angular blepharoconjunctivitis 10.1 F5 IL6 VEGFA
31 proctitis 10.1 ALB IL6 VEGFA
32 vernal conjunctivitis 10.1 ALB KDR VEGFA
33 scar contracture 10.1 F5 IL6 VEGFA
34 citrullinemia, type ii, neonatal-onset 10.1 ALB KDR VEGFA
35 adenoma 10.1
36 peritonitis 10.1
37 polycystic ovary syndrome 10.1
38 exophthalmic ophthalmoplegia 10.1 ALB F5 VEGFA
39 saethre-chotzen syndrome 10.1 IL6 KDR VEGFA
40 congenital nystagmus 10.1 ALB REN
41 obstructive jaundice 10.1 ALB F5 VEGFA
42 chronic tic disorder 10.1 ALB F5 VEGFA
43 leydig cell hypoplasia with pseudohermaphroditism 10.1 CYP19A1 FSHR
44 uterine ligament clear cell adenocarcinoma 10.1 ALB F5 IL6
45 capillary lymphangioma 10.1 AMH FSHR GNRH1
46 hypothyroidism 10.1
47 thrombophilia 10.1
48 ectopic pregnancy 10.1
49 retroperitoneal sarcoma 10.1 AMH CGA GNRH1
50 thymus adenosquamous carcinoma 10.1 IL6 KDR VEGFA

Graphical network of the top 20 diseases related to Ovarian Hyperstimulation Syndrome:



Diseases related to Ovarian Hyperstimulation Syndrome

Symptoms & Phenotypes for Ovarian Hyperstimulation Syndrome

Symptoms by clinical synopsis from OMIM:

608115

Clinical features from OMIM:

608115

Human phenotypes related to Ovarian Hyperstimulation Syndrome:

56 32 (show all 19)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 abdominal pain 56 32 Very frequent (99-80%) HP:0002027
2 nausea 56 32 Very frequent (99-80%) HP:0002018
3 ascites 56 32 Very frequent (99-80%) HP:0001541
4 increased circulating gonadotropin level 56 32 Very frequent (99-80%) HP:0000837
5 enlarged polycystic ovaries 56 32 Very frequent (99-80%) HP:0008675
6 abdominal distention 56 32 Very frequent (99-80%) HP:0003270
7 hypovolemia 56 32 Occasional (29-5%) HP:0011106
8 pleural effusion 56 32 Frequent (79-30%) HP:0002202
9 hirsutism 56 32 Very frequent (99-80%) HP:0001007
10 peripheral edema 56 32 Occasional (29-5%) HP:0012398
11 pulmonary edema 56 32 Occasional (29-5%) HP:0100598
12 hemorrhagic ovarian cyst 56 32 Frequent (79-30%) HP:0012886
13 generalized edema 56 32 Occasional (29-5%) HP:0007430
14 capillary leak 56 32 Very frequent (99-80%) HP:0030005
15 nausea and vomiting 56 Very frequent (99-80%)
16 increased testosterone 56 Very frequent (99-80%)
17 abnormality of the genitourinary system 32 HP:0000119
18 ovarian cyst 56 Frequent (79-30%)
19 increased serum testosterone level 32 HP:0030088

UMLS symptoms related to Ovarian Hyperstimulation Syndrome:


abdominal pain, nausea

MGI Mouse Phenotypes related to Ovarian Hyperstimulation Syndrome:

44 (show all 14)
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.26 ALB AMH CDH5 CGA CYP19A1 F5
2 growth/size/body region MP:0005378 10.21 KDR REN VEGFA CDH5 CGA CYP19A1
3 endocrine/exocrine gland MP:0005379 10.18 ALB AMH CDH5 CGA CYP19A1 FSHR
4 cardiovascular system MP:0005385 10.14 CDH5 CYP19A1 F5 FSHR IL6 KDR
5 hematopoietic system MP:0005397 10.1 CDH5 CYP19A1 FSHR GNRH1 IL6 KDR
6 immune system MP:0005387 10.06 CDH5 CYP19A1 FSHR GNRH1 IL6 KDR
7 integument MP:0010771 10.03 CDH5 CYP19A1 F5 FSHR GNRH1 IL6
8 liver/biliary system MP:0005370 10.01 ALB CDH5 CYP19A1 F5 GNRH1 IL6
9 nervous system MP:0003631 9.91 REN VEGFA CGA CYP19A1 F5 FSHR
10 muscle MP:0005369 9.85 ALB CYP19A1 IL6 KDR REN VEGFA
11 neoplasm MP:0002006 9.8 ALB AMH FSHR GNRH1 IL6 VEGFA
12 normal MP:0002873 9.7 ALB CDH5 CYP19A1 GNRH1 KDR REN
13 renal/urinary system MP:0005367 9.43 ALB CYP19A1 GNRH1 IL6 REN VEGFA
14 reproductive system MP:0005389 9.28 GNRH1 IL6 REN VEGFA AMH CDH5

Drugs & Therapeutics for Ovarian Hyperstimulation Syndrome

Drugs for Ovarian Hyperstimulation Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 146)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Progesterone Approved, Vet_approved Phase 4,Phase 3 57-83-0 5994
2
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-28-2 5757 53477783
3
Metformin Approved Phase 4 657-24-9 14219 4091
4
Leuprolide Approved, Investigational Phase 4,Phase 3 53714-56-0 3911 657181
5
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 112809-51-5 3902
6
Cetrorelix Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 120287-85-6 16129715 25074887
7
Ganirelix Approved Phase 4,Phase 3,Phase 2 123246-29-7, 124904-93-4 25081094
8
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
9
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
10
Tamoxifen Approved Phase 4 10540-29-1 2733526
11
Buserelin Approved Phase 4 57982-77-1
12
Cabergoline Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 81409-90-7 54746
13
Desogestrel Approved Phase 4 54024-22-5 40973
14
Nafarelin Approved Phase 4 76932-56-4 16129618 25077649
15
Menotropins Approved Phase 4,Phase 3 61489-71-2 5360545
16
Levonorgestrel Approved, Investigational Phase 4 797-63-7, 17489-40-6 13109
17
Norgestrel Approved Phase 4 6533-00-2 13109
18
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
19
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
20
leucovorin Approved, Nutraceutical Phase 4 58-05-9 54575, 6560146 143
21
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
22
Enclomiphene Investigational Phase 4,Phase 2,Phase 3,Phase 1 15690-57-0
23 Progestins Phase 4,Phase 3,Phase 2
24 Deslorelin Phase 4,Phase 3,Phase 2,Early Phase 1
25 Estradiol valerate Phase 4,Phase 3,Phase 2 979-32-8
26 Triptorelin Pamoate Phase 4,Phase 3,Phase 2
27 Clomiphene Phase 4,Phase 2,Phase 3,Phase 1
28 Chorionic Gonadotropin Phase 4,Phase 2,Phase 3,Early Phase 1
29 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
30 Contraceptive Agents Phase 4,Phase 3
31 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
32 Hormones Phase 4,Phase 3,Phase 2,Phase 1
33 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
34 Estradiol 17 beta-cypionate Phase 4,Phase 3,Phase 2
35 Hypoglycemic Agents Phase 4
36 Estradiol 3-benzoate Phase 4,Phase 3,Phase 2
37 Estrogen Antagonists Phase 4,Phase 2,Phase 3,Phase 1
38 Estrogens Phase 4,Phase 2,Phase 3,Phase 1
39 Polyestradiol phosphate Phase 4,Phase 3,Phase 2
40 Zuclomiphene Phase 4,Phase 2,Phase 3,Phase 1
41 Prolactin Release-Inhibiting Factors Phase 4,Phase 2,Phase 3
42 Fertility Agents Phase 4,Phase 3,Phase 2,Phase 1
43 Luteolytic Agents Phase 4,Phase 3
44 Aromatase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
45 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 1,Phase 2
46 Analgesics Phase 4
47 Dopamine agonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
48 Chelating Agents Phase 4,Phase 2,Phase 3
49 Selective Estrogen Receptor Modulators Phase 4,Phase 2,Phase 3,Phase 1
50 Follicle Stimulating Hormone Phase 4,Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 167)
id Name Status NCT ID Phase
1 Co-administration of Low Dose hCG at the Time of GnRH Agonist Trigger or 35 Hours Later for the Prevention of OHSS Unknown status NCT01815138 Phase 4
2 Comparison Between GnRH Agonist and GnRH Antagonist Protocols of Ovarian Stimulation in PCOS Patients Unknown status NCT00417144 Phase 4
3 Corifollitropin Alfa Application in PCOS Patients Unknown status NCT02215135 Phase 4
4 Surgical Ovarian Drilling Versus Hormonal Treatment for Infertility Associated to PolyCystic Ovaries Syndrome (PCOS) Unknown status NCT00378729 Phase 4
5 Comparing Coasting by Withholding GnRH Agonist With GnRH Antagonist Unknown status NCT01347268 Phase 4
6 Metformin in Step-down Regimen Versus Conventional Low Dose Step-up Protocol in Patients With PCOS Undergoing IVF Unknown status NCT01438190 Phase 4
7 Comparison of Ovarian Mild Stimulation and Controlled Ovarian Stimulation in Poor Ovarian Responders Unknown status NCT01926210 Phase 4
8 Type of Gonadotropin and Embryo Kinetics of Development Unknown status NCT02402192 Phase 4
9 Preventive Application of Letrozole Decrease Incidence of Early Onset of OHSS Completed NCT02670304 Phase 4
10 The Use of GnRH Agonist Trigger in the Prevention of OHSS Completed NCT00349258 Phase 4
11 Endometrial Receptivity After GnRH Agonist Triggering Completed NCT01500863 Phase 4
12 Short Versus Long Protocol for IVF and IVF+ICSI Completed NCT00756028 Phase 4
13 Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS) Completed NCT00805935 Phase 4
14 Endometrial Advancement After Rec or u-HCG Triggering Completed NCT00953628 Phase 4
15 Anti-Mullerian Hormone (AMH) Versus Antral Follicle Count (AFC) Guided rFSH Dosing Study Completed NCT01783301 Phase 4
16 The Influence of Dopamine Agonist Cabergoline on Oocyte Maturation Completed NCT01065376 Phase 4
17 Metformin in High Responder Polycystic Ovary Syndrome (PCOS) Patients Undergoing IVF Cycles Completed NCT01233206 Phase 4
18 COmbining Oral Letrozole and Clomiphene for Ovarian Stimulation Completed NCT02288143 Phase 4
19 Recombinant Follicle Stimulating Hormone (FSH) (Gonal-f®): Use in Ovulation Induction Completed NCT01081626 Phase 4
20 Triggering of Final Oocyte Maturation With GnRHa (Buserelin) in GnRH Antagonist Cycles Completed NCT00627406 Phase 4
21 Trial Comparing hCG Triggering Versus hCG Associated With GnRH Agonist Completed NCT01607203 Phase 4
22 Menopur Mixed Protocol Completed NCT01417195 Phase 4
23 Luteal Phase FSH in the IVF Poor Responder Completed NCT00225433 Phase 4
24 MENOPUR® Versus FOLLISTIM® Completed NCT00802360 Phase 4
25 The Effect of Pre-treatment With GnRH Analogues Prior in Vitro Fertilization in Patients With Endometriosis Completed NCT01581359 Phase 4
26 Ovarian Stimulation and Intrauterine Insemination in Women With Polycystic Ovarian Syndrome Completed NCT01675843 Phase 4
27 Predictive Factors for Ovarian Stimulation Using a Fixed Daily Dose of 200 IU Recombinant FSH (Study 142003)(P05696) Completed NCT00778999 Phase 4
28 Role of Melatonin Supplementation in Follicular Fluid of in Vitro Fertilization (IVF) Patients With Polycystic Ovarian Syndrome Completed NCT01540747 Phase 4
29 Clomiphene Citrate Versus Tamoxifen for Ovulation Induction in PCOs Completed NCT02479256 Phase 4
30 Use of Myo-inositol as Adjuvant Therapy in Patients With Polycystic Ovary Syndrome (PCOS) in Vitro Fertilization (IVF) Recruiting NCT02221154 Phase 4
31 Dual Trigger Versus GnRHa Trigger Combined With Luteal HCG Administration Recruiting NCT02330770 Phase 4
32 Efficacy and Safety of Medication Used to Stimulate Ovulation Recruiting NCT02715336 Phase 4
33 Follicular Steroid Genesis in Controlled Ovarian Stimulation Recruiting NCT02738580 Phase 4
34 Use of Low Dose of HCG During Ovulation Induction With CC in Women With CC Resistant PCOS Recruiting NCT02436226 Phase 4
35 Gonapure® in Multifollicular Stimulation in Egyptian Women Undergoing IVF/ICSI Recruiting NCT03057574 Phase 4
36 Efficacy of Corifollitropin Alfa Versus Follitropin Beta in Aged IVF (In-vitro Fertilization) Patients Active, not recruiting NCT02466204 Phase 4
37 FSH in GnRH-AntagoniST Controlled Ovarian Hyperstimulation Cycles (FAST) Active, not recruiting NCT01969201 Phase 4
38 Long Protocol and Freeze All Embryos vs Antagonist Protocol With Fresh Embryo Transfer in PCOS Patients Undergoing ICSI Not yet recruiting NCT03118830 Phase 4
39 Efficacy of Corifollitropin Alfa in Obese Women in Terms of Clinical and Molecular Parameters of IVF Success Not yet recruiting NCT02606500 Phase 4
40 Study to Compare hFSH-HP (Fostipur) and hMG-HP(Meriofert) in Patients With Polycystic Ovary Under a IVF/ICSI Cycle. Not yet recruiting NCT02785822 Phase 4
41 Can GnRH Agonist Trigger Prevent Ovarian Hyperstimulation Syndrome? Terminated NCT01714648 Phase 4
42 Metformin in Assisted Reproduction-MET-AR-study Terminated NCT00159575 Phase 4
43 Low-dose Gonal-f® in Ovulation Induction Terminated NCT01871532 Phase 4
44 Pituitary Down-regulation Before IVF for Women With Endometriosis Terminated NCT01757249 Phase 4
45 Does Letrozole Improve the Outcomes and/or Reduce the Cost of IVF-ET Cycles? Withdrawn NCT00804960 Phase 4
46 IVF Versus LOD in Women With CC Resistant PCOS Withdrawn NCT02456792 Phase 4
47 IVF Versus Gonadotropin Therapy in Women With CC Resistant PCOS Withdrawn NCT02458963 Phase 4
48 GnRH Agonist and Progesterone Versus Progesterone Only for Luteal Phase Support in Antagonist Cycles Unknown status NCT02262416 Phase 3
49 GnRH Antagonist for Treatment of Early Ovarian Hyperstimulation Syndrome Completed NCT01268761 Phase 3
50 Diosmin Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome Completed NCT02134249 Phase 2, Phase 3

Search NIH Clinical Center for Ovarian Hyperstimulation Syndrome

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: ovarian hyperstimulation syndrome

Genetic Tests for Ovarian Hyperstimulation Syndrome

Genetic tests related to Ovarian Hyperstimulation Syndrome:

id Genetic test Affiliating Genes
1 Ovarian Hyperstimulation Syndrome 29 24 FSHR

Anatomical Context for Ovarian Hyperstimulation Syndrome

MalaCards organs/tissues related to Ovarian Hyperstimulation Syndrome:

39
Endothelial, Ovary, Pituitary, Liver, Kidney, Thyroid, Breast

Publications for Ovarian Hyperstimulation Syndrome

Articles related to Ovarian Hyperstimulation Syndrome:

(show top 50) (show all 729)
id Title Authors Year
1
The Clinical Characteristics of Acute Cerebrovascular Accidents Resulting from Ovarian Hyperstimulation Syndrome. ( 28253509 )
2017
2
In vivo intrabursal administration of bioactive lipid sphingosine-1-phosphate enhances vascular integrity in a rat model of ovarian hyperstimulation syndrome (OHSS). ( 28379469 )
2017
3
Early hCG administration as an alternative prevention strategy of ovarian hyperstimulation syndrome during an IVF cycle. ( 28150929 )
2017
4
A proteomic analysis identifies candidate early biomarkers to predict ovarian hyperstimulation syndrome in polycystic ovarian syndrome patients. ( 28534980 )
2017
5
Severe ovarian hyperstimulation syndrome after combined GnRH-agonist and low-dose human chorionic gonadotropin trigger in a patient with a single kidney. ( 28440686 )
2017
6
Sliding scale HCG trigger yields equivalent pregnancy outcomes and reduces ovarian hyperstimulation syndrome: Analysis of 10,427 IVF-ICSI cycles. ( 28441461 )
2017
7
Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. ( 28535578 )
2017
8
Prevention and management of ovarian hyperstimulation syndrome. ( 28262238 )
2017
9
Association of -460C/T and +405 G/C polymorphisms of vascular endothelial growth factor gene and susceptibility to ovarian hyperstimulation syndrome. ( 28462400 )
2017
10
Two cases of first onset intrahepatic cholestasis of pregnancy associated with moderate ovarian hyperstimulation syndrome after IVF treatment and review of the literature. ( 28319428 )
2017
11
Reduced Intellectual Ability in Offspring of Ovarian Hyperstimulation Syndrome: A Cohort Study. ( 28532740 )
2017
12
Atypical case of preterm ovarian hyperstimulation syndrome. ( 28228430 )
2017
13
Vascular endothelial growth factor antagonist reduces the early onset and the severity of ovarian hyperstimulation syndrome. ( 28403961 )
2017
14
Ovarian torsion and spontaneous ovarian hyperstimulation syndrome in a twin pregnancy: A case report. ( 28371633 )
2017
15
First mutation in the FSHR cytoplasmic tail identified in a non-pregnant woman with spontaneous ovarian hyperstimulation syndrome. ( 28446136 )
2017
16
A review on ovarian hyperstimulation syndrome (OHSS) management strategies. ( 28322539 )
2017
17
Final oocyte maturation with two different GnRH agonists in antagonist co-treated cycles at risk of ovarian hyperstimulation syndrome. ( 27771155 )
2017
18
Long hospitalization for severe ovarian hyperstimulation syndrome with persistent right hydrothorax and two occurrences of pneumonia. ( 28099716 )
2017
19
A New Perspective on the Risk of Hypercoagulopathy in Ovarian Hyperstimulation Syndrome Using Thromboelastography. ( 28299993 )
2017
20
Concurrent ovarian hyperstimulation syndrome with perforated appendicitis following induction ovulation with HMG and HCG. ( 27066875 )
2016
21
Pharmacologic Interventions in Preventing Ovarian Hyperstimulation Syndrome: A Systematic Review and Network Meta-Analysis. ( 26752241 )
2016
22
PIVET rFSH dosing algorithms for individualized controlled ovarian stimulation enables optimized pregnancy productivity rates and avoidance of ovarian hyperstimulation syndrome. ( 27563236 )
2016
23
A potential role of endoplasmic reticulum stress in development of ovarian hyperstimulation syndrome. ( 27032713 )
2016
24
Volume expanders for the prevention of ovarian hyperstimulation syndrome. ( 27577848 )
2016
25
Dopamine agonists for preventing ovarian hyperstimulation syndrome. ( 27901279 )
2016
26
Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. ( 27678032 )
2016
27
Critical Ovarian Hyperstimulation Syndrome After InA Vitro Fertilization Treatment in a Renal Transplant Recipient: A Case Report. ( 26915882 )
2016
28
Erratum to: Prophylactic vitamin D supplementation in ovarian hyperstimulation syndrome: an animal study. ( 26825727 )
2016
29
Swollen labia majora: An unusual presentation of occult inguinal hernia secondary to ovarian hyperstimulation syndrome. ( 27343335 )
2016
30
Ovarian hyperstimulation syndrome: review and new classification criteria for reporting in clinical trials. ( 27343272 )
2016
31
Fatal ovarian hyperstimulation syndrome in an anonymous egg donor. ( 27542392 )
2016
32
Intranasal gonadotropin-releasing hormone agonist (GnRHa) for luteal-phase support following GnRHa triggering, a novel approach to avoid ovarian hyperstimulation syndrome in high responders. ( 27114332 )
2016
33
Use of Point-of-Care Ultrasound for the Diagnosis of Ovarian Hyperstimulation Syndrome. ( 27998636 )
2016
34
Diginyc partial hydatidiform mole with increased fetal nuchal translucency and ovarian hyperstimulation syndrome. ( 27328519 )
2016
35
GnRH agonist with low-dose hCG (dual trigger) is associated with higher risk of severe ovarian hyperstimulation syndrome compared to GnRH agonist alone. ( 27349252 )
2016
36
Spontaneous ovarian hyperstimulation syndrome in a young female subject with a lingual thyroid and primary hypothyroidism. ( 27510824 )
2016
37
The combination of Everolimus with Verapamil reduces ovarian weight and vascular permeability on ovarian hyperstimulation syndrome: a preclinical experimental randomized controlled study. ( 27223459 )
2016
38
Vascular endothelial growth factor antagonist reduces the early onset and the severity of ovarian hyperstimulation syndrome. ( 27241947 )
2016
39
An Update on the Prevention of Ovarian Hyperstimulation Syndrome. ( 27543490 )
2016
40
A Rare Case of Ovarian Hyperstimulation Syndrome in a Preterm Infant. ( 28050466 )
2016
41
Electroacupuncture decreases the progression of ovarian hyperstimulation syndrome in a rat model. ( 27020131 )
2016
42
Predictors of Paracentesis in Women with Severe Ovarian Hyperstimulation Syndrome: A Retrospective Cohort Study. ( 27399220 )
2016
43
Prediction of Ovarian Hyperstimulation Syndrome in Patients Treated with Corifollitropin alfa or rFSH in a GnRH Antagonist Protocol. ( 26950065 )
2016
44
Spontaneous ovarian hyperstimulation syndrome revealing a pituitary macroadenoma. ( 27730091 )
2016
45
Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles. ( 27060174 )
2016
46
Ovarian hyperstimulation syndrome in a spontaneous pregnancy: A potential for missed-diagnosis. ( 27185984 )
2016
47
Critical Ovarian Hyperstimulation Syndrome and Management. ( 27046970 )
2016
48
Comparison between resveratrol and cabergoline in preventing ovarian hyperstimulation syndrome in a rat model. ( 26939766 )
2016
49
Effect of letrozole on moderate and severe early-onset ovarian hyperstimulation syndrome in high-risk women:A aA prospective randomized trial. ( 27555316 )
2016
50
C-reactive protein response is higher in early than in late ovarian hyperstimulation syndrome. ( 27865939 )
2016

Variations for Ovarian Hyperstimulation Syndrome

UniProtKB/Swiss-Prot genetic disease variations for Ovarian Hyperstimulation Syndrome:

66
id Symbol AA change Variation ID SNP ID
1 FSHR p.Thr449Ile VAR_017244 rs28928870
2 FSHR p.Asp567Asn VAR_017245 rs28928871
3 FSHR p.Ser128Tyr VAR_039279
4 FSHR p.Thr449Ala VAR_039282
5 FSHR p.Ile545Thr VAR_039284
6 FSHR p.Met512Ile VAR_074535
7 FSHR p.Val514Ala VAR_074536
8 FSHR p.Ala575Val VAR_074537

ClinVar genetic disease variations for Ovarian Hyperstimulation Syndrome:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 FSHR NM_000145.3(FSHR): c.919G> A (p.Ala307Thr) single nucleotide variant drug response rs6165 GRCh37 Chromosome 2, 49191041: 49191041
2 FSHR NM_000145.3(FSHR): c.2039G> A (p.Ser680Asn) single nucleotide variant drug response,risk factor rs6166 GRCh37 Chromosome 2, 49189921: 49189921
3 FSHR NM_000145.3(FSHR): c.1346C> T (p.Thr449Ile) single nucleotide variant Pathogenic rs28928870 GRCh37 Chromosome 2, 49190614: 49190614
4 FSHR NM_000145.3(FSHR): c.1699G> A (p.Asp567Asn) single nucleotide variant Pathogenic rs28928871 GRCh37 Chromosome 2, 49190261: 49190261
5 FSHR NM_000145.3(FSHR): c.1345A> G (p.Thr449Ala) single nucleotide variant Pathogenic rs121909663 GRCh37 Chromosome 2, 49190615: 49190615
6 FSHR NM_000145.3(FSHR): c.1634T> C (p.Ile545Thr) single nucleotide variant Pathogenic rs121909664 GRCh37 Chromosome 2, 49190326: 49190326
7 FSHR NM_000145.3(FSHR): c.383C> A (p.Ser128Tyr) single nucleotide variant Pathogenic rs121909665 GRCh37 Chromosome 2, 49217768: 49217768

Expression for Ovarian Hyperstimulation Syndrome

Search GEO for disease gene expression data for Ovarian Hyperstimulation Syndrome.

Pathways for Ovarian Hyperstimulation Syndrome

GO Terms for Ovarian Hyperstimulation Syndrome

Cellular components related to Ovarian Hyperstimulation Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.5 ALB AMH F5 GNRH1 IL6 REN
2 platelet alpha granule lumen GO:0031093 9.33 ALB F5 VEGFA
3 extracellular region GO:0005576 9.28 ALB AMH CGA F5 GNRH1 IL6

Biological processes related to Ovarian Hyperstimulation Syndrome according to GeneCards Suite gene sharing:

(show all 18)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.84 CGA IL6 KDR VEGFA
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.75 FSHR IL6 KDR
3 aging GO:0007568 9.73 AMH GNRH1 IL6
4 positive regulation of cell migration GO:0030335 9.72 CGA KDR VEGFA
5 regulation of cell shape GO:0008360 9.65 IL6 KDR VEGFA
6 response to organic cyclic compound GO:0014070 9.63 AMH GNRH1 IL6
7 platelet degranulation GO:0002576 9.61 ALB F5 VEGFA
8 hormone-mediated signaling pathway GO:0009755 9.57 FSHR REN
9 negative regulation of apoptotic process GO:0043066 9.55 ALB GNRH1 IL6 KDR VEGFA
10 positive regulation of focal adhesion assembly GO:0051894 9.52 KDR VEGFA
11 female gonad development GO:0008585 9.51 CYP19A1 FSHR
12 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.49 KDR VEGFA
13 uterus development GO:0060065 9.4 CYP19A1 FSHR
14 cell migration involved in sprouting angiogenesis GO:0002042 9.37 KDR VEGFA
15 negative regulation of bone resorption GO:0045779 9.32 FSHR IL6
16 positive regulation of positive chemotaxis GO:0050927 9.26 KDR VEGFA
17 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 8.96 KDR VEGFA
18 gonad development GO:0008406 8.8 AMH CGA FSHR

Molecular functions related to Ovarian Hyperstimulation Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.33 AMH IL6 VEGFA
2 receptor binding GO:0005102 9.26 AMH CDH5 IL6 REN
3 hormone activity GO:0005179 8.8 AMH CGA GNRH1

Sources for Ovarian Hyperstimulation Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....